CPRX
Catalyst Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.49
+0.00%Aug 14, 2026, 17:02 UTC
Chuck Royce reduced his fund's stake in Catalyst Pharmaceuticals during the second quarter of 2026, as disclosed in the 13F filing.
Source:Jul 16, 2026, 07:36 UTC
Angelini Pharma completed its acquisition of Catalyst Pharmaceuticals, gaining ownership of Catalyst's product portfolio and strengthening its presence in the U.S. market.
Source:Jul 10, 2026, 10:03 UTC
Catalyst Pharmaceuticals stockholders approved the merger with Angelini Pharma S.p.A. at a special meeting on July 8.
Source: